Jazz Pharmaceuticals Sees FY24 Adj EPS $19.20-$20.30 Vs $18.51 Est.; Revenue $4.0B-$4.1B Vs $4.047B Est.
Portfolio Pulse from Benzinga Newsdesk
Jazz Pharmaceuticals has provided its financial guidance for FY24, projecting adjusted EPS between $19.20 and $20.30, surpassing the estimated $18.51. The company also forecasts revenue between $4.0 billion and $4.1 billion, aligning closely with the estimated $4.047 billion.
July 31, 2024 | 8:26 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Jazz Pharmaceuticals has issued its FY24 financial guidance, with adjusted EPS expected to be between $19.20 and $20.30, higher than the estimated $18.51. Revenue is forecasted to be between $4.0 billion and $4.1 billion, close to the $4.047 billion estimate.
The higher-than-expected EPS guidance is likely to positively impact Jazz Pharmaceuticals' stock price in the short term. The revenue forecast aligns closely with estimates, providing a stable outlook.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100